Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CASP2 | P42575 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2411306 | 0.93 | MEN1 (0.50) | MEN1KMT2ANAAAKDM4EMAPK1 | |
| SCHEMBL2416542 | 0.91 | NAAA (0.52) | MEN1KMT2ANAAAKDM4EMAPK1 | |
| SCHEMBL14902211 | 0.91 | NAAA (0.52) | MEN1KMT2ANAAAKDM4EMAPK1 | |
| SCHEMBL2242514 | 0.85 | GAA (0.44) | MEN1KMT2ANAAACNR1ALDH1A1 | |
| SCHEMBL27253415 | 0.85 | KDM4E (0.59) | MEN1KMT2ANAAAKDM4EMAPK1 | |
| SCHEMBL10682467 | 0.85 | KDM4E (0.59) | MEN1KMT2ANAAAKDM4EMAPK1 | |
| SCHEMBL9717465 | 0.85 | MEN1 (0.48) | MEN1KMT2ANAAAMAPK1CNR1 | |
| SCHEMBL4453310 | 0.82 | MEN1 (0.43) | MEN1KMT2AKDM4EMAPK1HIF1A | |
| SCHEMBL10605642 | 0.81 | CASP2 (0.54) | MEN1KMT2ANAAACNR1CASP2 | |
| SCHEMBL14516258 | 0.80 | TSHR (0.52) | MEN1KMT2ANAAAMAPK1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119529145-A | Hydrolysis-resistant acetoacetamide modified polyvinyl alcohol and preparation method thereof | 南京工业大学 | 2025-02-28 | — | — | CN | disclosed |
| US-9943498-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2018-04-17 | — | — | US | disclosed |
| US-9943498-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2018-04-17 | — | — | US | disclosed |
| US-9943498-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2018-04-17 | — | — | US | disclosed |
| EP-2549991-B1 | FE(III) COMPLEX COMPOUNDS FOR TREATING AND PROPHYLAXIS FOR ANAEMIA SYMPTOMS AND ANAEMIA | VIFOR (INTERNATIONAL) AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| EP-2549991-B1 | FE(III) COMPLEX COMPOUNDS FOR TREATING AND PROPHYLAXIS FOR ANAEMIA SYMPTOMS AND ANAEMIA | VIFOR (INTERNATIONAL) AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-9394324-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2013-05-02 | — | — | US | disclosed |
| EP-2549991-A1 | FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS | Vifor (International) AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| CN-102892415-A | Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR INT AG | 2013-01-23 | — | — | CN | disclosed |
| WO-2011117225-A1 | FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS | VIFOR (INTERNATIONAL) AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011117225-A1 | FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS | VIFOR (INTERNATIONAL) AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| EP-2054204-B1 | METHOD FOR WATERPROOFING WOOD | WACKER CHEMIE AG (DE) | 2009-12-23 | — | — | EP | disclosed |
| EP-2054204-A1 | METHOD FOR WATERPROOFING WOOD | Wacker Chemie AG (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008022906-A1 | METHOD FOR WATERPROOFING WOOD | WACKER CHEMIE AG (DE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | FECH, SDHB, SLC40A1 | MEN1 991/4885KMT2A 2843/4885NAAA 2269/4885 |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | FECH, SDHB, SLC40A1 | MEN1 991/4885KMT2A 2843/4885NAAA 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.